肾炎消白颗粒对阿霉素肾病大鼠足细胞Podocin表达的影响
|
摘要
目的:探讨肾炎消白颗粒减少阿霉素肾病大鼠蛋白尿的作用,并从生化、分子生物学角度探讨其作用机理,为临床应用进一步提供理论依据。
方法:60只Wistar大鼠,随机分为5组,分别为空白对照组、模型对照组、洛汀新组、肾炎消白颗粒低剂量组、肾炎消白颗粒高剂量组,用尾静脉一次性注射阿霉素制备肾炎蛋白尿模型,而后各组以预定方法灌胃,观察7周,于每周一检测大鼠的尿肌酐,酶联免疫法检测尿白蛋白,第七周末检测血清白蛋白,免疫组织化学法检测大鼠肾组织中Podocin蛋白表达情况。
结果:实验7周末各治疗组(肾炎消白颗粒高、低剂量组及洛汀新组)阿霉素肾病大鼠尿白蛋白/尿肌酐值下降,以肾炎消白颗粒高剂量组最为明显(P<0.05);血清白蛋白含量上升,以肾炎消白颗粒高剂量组最为明显(P<0.05);Podocin蛋白在肾组织中的表达增加,以肾炎消白颗粒高剂量组最好,中药高剂量组对上述作用均优于中药低剂量组、洛汀新组。
结论:肾炎消白颗粒能够在一定程度上减少阿霉素肾病大鼠尿蛋白的排泄量;提高阿霉素肾病大鼠血清白蛋白的含量,其机制可能是减少尿中蛋白排泄量;改善阿霉素肾病大鼠足细胞的形态,增加阿霉素肾病大鼠肾组织中Podocin蛋白表达,对于受损足细胞有修复作用,从而减少尿蛋白的排泄量。
Objective:To test if nephritis Xiaobaikeli decreases proteinuria level in experimental animals and investigate its mechanism by biochemical and molecular biological analysis to provide the basis for its clinical application.
Methods:We utilized a rat model in which nephritis is induced by one-time tail vein injection of doxorubicin.Animals were divided into five groups,namely the naive control group,model control group,Lotensin group,low-dose nephritis Xiaobaikeli group and high-dose nephritis Xiaobaikeli group.Seven weeks after treatment,we detected rat urine creatinine,proteinuria,Enzyme immunosorbent method to detect urinary albumin and Using immunohistochemistry in kidney tissues Podocin detection of expression.
Results:At the end of 7-week observation,the ratio of proteinuria/urine creatinine values(P<0.05)were reduced in animals from all treatment group with doxorubicin-induced nephritis , and the high-dose nephritis Xiaobaikeli treatment had the most significant effects(Palbumin concentration(P<0. 05)was increased in all treatment group; and high-dose nephritis Xiaobaikeli treatment had the most significant effects (P<0.05);and the high-dose nephritis Xiaobaikeli treatment had the most significant effects (P<0.05);the treatment by nephritis Xiaobaikeli did not affect the kidney function in rats with nephritis(P>0 . 05) ; and the high—dose nephritis Xiaobaikeli treatment had the most significant effects (P Conclusion:nephritis Xiaobaikeli can reduce excretion a certain extent, in nephrotic rats and protect tubulo: It can possibly increase serum albumin level by reducing excretion;SO it can treat kidney fibrosis;It can improve the foot cell morphology of nephrotic rats,by which it reduced excretion;It can reduce Podocin mRNA and expression in kidney tissues from rats with doxorubicin.Induced nephritis,repair injured foot cell,then.reduce excretion.The therapeutic effects with high-dose nephritis Xiaobaikeli are better than low-dose nephritis Xiaobaikeli or Lotensin.
方法:60只Wistar大鼠,随机分为5组,分别为空白对照组、模型对照组、洛汀新组、肾炎消白颗粒低剂量组、肾炎消白颗粒高剂量组,用尾静脉一次性注射阿霉素制备肾炎蛋白尿模型,而后各组以预定方法灌胃,观察7周,于每周一检测大鼠的尿肌酐,酶联免疫法检测尿白蛋白,第七周末检测血清白蛋白,免疫组织化学法检测大鼠肾组织中Podocin蛋白表达情况。
结果:实验7周末各治疗组(肾炎消白颗粒高、低剂量组及洛汀新组)阿霉素肾病大鼠尿白蛋白/尿肌酐值下降,以肾炎消白颗粒高剂量组最为明显(P<0.05);血清白蛋白含量上升,以肾炎消白颗粒高剂量组最为明显(P<0.05);Podocin蛋白在肾组织中的表达增加,以肾炎消白颗粒高剂量组最好,中药高剂量组对上述作用均优于中药低剂量组、洛汀新组。
结论:肾炎消白颗粒能够在一定程度上减少阿霉素肾病大鼠尿蛋白的排泄量;提高阿霉素肾病大鼠血清白蛋白的含量,其机制可能是减少尿中蛋白排泄量;改善阿霉素肾病大鼠足细胞的形态,增加阿霉素肾病大鼠肾组织中Podocin蛋白表达,对于受损足细胞有修复作用,从而减少尿蛋白的排泄量。
Objective:To test if nephritis Xiaobaikeli decreases proteinuria level in experimental animals and investigate its mechanism by biochemical and molecular biological analysis to provide the basis for its clinical application.
Methods:We utilized a rat model in which nephritis is induced by one-time tail vein injection of doxorubicin.Animals were divided into five groups,namely the naive control group,model control group,Lotensin group,low-dose nephritis Xiaobaikeli group and high-dose nephritis Xiaobaikeli group.Seven weeks after treatment,we detected rat urine creatinine,proteinuria,Enzyme immunosorbent method to detect urinary albumin and Using immunohistochemistry in kidney tissues Podocin detection of expression.
Results:At the end of 7-week observation,the ratio of proteinuria/urine creatinine values(P<0.05)were reduced in animals from all treatment group with doxorubicin-induced nephritis , and the high-dose nephritis Xiaobaikeli treatment had the most significant effects(P
引文
1.Garg AX,Kiberd BA,Clark WF,et al.Albuminuria and renalin sufficiency Prevalence guides poplation scening : Rsults from the NHANESⅢ.Kindney Int,2002,61:2165-2175
2.张路霞,左力,徐国宾等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究.中华肾脏病杂志[J],2006,22(2):67-71
3.仝小林,张志远.蛋白尿的中医治疗.中国医药学报[J],2002,17(2):115
4.刘伟,贝岩.中药辨证治疗蛋白尿探析.辽宁中医杂志[J],2005,32(3):225
5.李亦聪,冯天保.谢桂权教授治疗慢性肾炎蛋白尿经验介绍.新中医[J],2006,38(4):16
6.张琼.黄淑芬从络病论治肾性蛋白尿.中医杂志[J],2004,46(10):745
7.沈庆法.清利法治疗蛋白尿.上海中医药杂志[J],2006,40(2):23
8.袁红霞.林嫦娥.黄文政教授治疗顽固性蛋白尿经验总结.天津中医药[J],2003,20(5):18-19
9.刘宏伟,王国栋,张国强.国医时振声教授学术贡献撷萃.中医药学刊[J],2001,19(6):534
10.郭立中,毛炜,刘玉宁,等.叶传惠教授对肾炎蛋白尿的病机认识及治疗经验.中国中西医结合肾病杂志[J],2001,2(3):128
11.邓聪.从风郁瘀论治蛋白尿.中华中医药杂志[J],2006,21(8):506
12.代渊.唐章全主任医师治疗慢性肾蛋白尿经验.中医药学刊[J] , 2006 ,24(3):408-409
13.邹玺.熊宁宁.长期应用清热利湿和络法对慢性肾炎患者蛋白尿变化的影响.中医杂志[J], 2004,45(4):266-269
14.方志传.养脾为主治疗慢性肾炎蛋白尿.湖北中医杂志[J],2001,23(8):346
15.张丽霞.升阳益气固肾化瘀治疗慢性肾炎蛋白尿疗效观察.中医药学刊[J],2006,24(5):965-966
16.李玉花.活血化瘀法在蛋白尿治疗中的运用.实用中西医结合临床[J],2005,(5)2:55-56
17.王静.补肾固涩法为主治疗蛋白尿30例.陕西中医[J],2001,22(10):590
18.齐占华.益肾液治疗肾小球性蛋白尿疗效分析.实用中医药杂志[J],2005,21(10):585
19.练建红.刘恩棋.蒙向欣等.益肾I方治疗肾小球性蛋白尿的临床研究.福建中医药[J],2007,3(3):1-3
20.雷作熹,罗仁,董晓蕾等.小四五颗粒对糖尿病大鼠肾保护作用研究[J].中药新药与临床药理[J],2003,14(2):93-96
21.代方国.魏敏.孙晓敏,等.小四五颗粒治疗慢性肾病蛋白尿30例临床观察[J].新中医,2007,39(8):33-34
22.何岚.王宁生.五苓散减轻阿霉素肾病大鼠蛋白尿的实验研究.中成药[J],2006,28(10):1532-1534
23.赵飞,王晓霞,程广清等.疏血通注射液治疗肾性蛋白尿69例临床观察[J]山东中医药大学学报,2007,31(4):294-295
24.张万祥,秦建国,张荣等.参芪益肾汤治疗疗肾性蛋白尿45例观察.时珍国医国药,2007,18(6):1482-1483
25.曾红兵,刘晓城.火把花根对实验性肾炎大鼠肾脏病理改变的影响.中国中西医结合肾病杂志[J].2006,(7)1:13-15
26.陈志强,方敬,刘丽,等.青藤碱对系膜增生性肾小球肾炎影响的实验研究[J].中国老年学杂志,2007,27:27-28
27.Mundel P,Shankland SJ.Podocyte biology and resPonse toinjury.J Am Soe NePlirol,2002,13(12):3005-3015
28.Yuzawa Y,Matsuo S.Focal segmental glomerulosclerosis.Nippon Rinsho,2004,62 (10):1837-1841
29.Bariety J,Bruneval P.Hill G,et al.Posttransplantation relapse of FSGS is charaeterized by glomemlar epithelial cell transdifferentieatlon[J].J Am Soe Nephol,2001,12(2):261-274
30.Huber TB,Hardeben B,Kim J,et al.Nephrin and CD2AP associate with Phosphoinositide 3-OH kinase and stimulate AKT-dependent signaiing[J].MolCel lBiol,2003,23(14):4917-4928
31.Cantley LC.The phosphoinositide3-kinase pathway[J].Seienee,2002,296(5573):1655~1657
32.Kaplan JM,Kim SH,North KN, e tal.Mutations in ACTN4,encoding alpha-aetinin-4,cause familial foeal segmental glomerulaselerosis[J].NatGenet,2000,24:251-256
33.Yao J,Le TC,Kos CH,et al.AIPha-actinin-4- mediated FSGS:an inherited kidney disease caused by an aggre-gated and rapidly degraded cytaskeletal protein[J] Plos Biol,2004,2(6):787-794
34.Weins A,Kenlan P,Herbert S,et al.Mutational and Bio-logieal Analysis of alpha-actinin-4 in focal segmental glomeruloselerosis[J].J Am Soe Nephrol.2005,16(12):3694-3701
35.Luimula P,Sandstrom N,Novikon D et al.Podoeyte-assoeiated moleeules in puromycm aminonueleaside nephrosis of therat[J].LabInvest,2002,82(6):713-718
36.何伟春,邢昌赢,孙彬,等.CD2AP和α-actinin-4在大鼠阿霉素肾病模型中的表达.南京医科大学学报(自然科学版),2006,26(11):1005-1007
37.Boute N.Gribouval O.Roselli S.et al.NPHS2.encoding the gomerular protein Podoein,is mutated in autosomal recessive steroid- resistant nephritic syndrome.Nat Genet2000,24:349-354
38.Sehwarz K.Simons M.Keiser,J.et al.Podoein,araft-assoeiated component of the gomemlar slit diaphragm,interacts with CD2AP and nephrin.J Clin Invest,2001,108(11):1621-1629
39.Sedeuskv MM.Siefker,JM.Mordel organisms:new insights into charnel and transporter function.Stomatiu homologues interaet in Caeuorhahditis elegans. Am,J Physiol Cell Phvsiol.2001,280.C1340-C134R
40.叶任高,沈清瑞.肾脏病诊断与治疗学.北京:北京人民卫生出版社[M],1994:208
41.叶任高,刘冠贤.临床肾脏病学.北京:北京人民卫生出版社[M],1997:52-53
42.林善琐,陈靖.肾小球疾病治疗最新进展.中国实用内科杂志,2000,20:26-29
43.Edited by Barry M.Brenner The kidneyy[J] .Science press sixth dition,2000,1271-1277
44.Albert Matalon,Anthong Valeri,and Grerald B Appel:Treatment of Focal segmental Glomerulosclerosis[J] .Seminars in Nephrology.2000,20:309-317
45.何敏华,叶任高,马翅云.糖皮质激素在肾小球疾病治疗中的进展.大理学院学报[J],2003,(2)3:52
46.李幼姬,叶任高,姜搅.成人原发性肾病综合征治疗的探索.中华肾脏病杂志[J],1995,11(3):133-136
47.黎磊石,张训,陈光永,等.雷公藤治疗肾小球肾炎的临床研究.中华内科杂志[J],1981,20(4):216
48.黎磊石,刘志红.雷公藤在肾脏病领域应用的前景.肾脏病与透析肾移植杂志[J],1997,6(3):203
49.施向东,范德墉,陆玉良.雷公藤多甙片对肾性蛋白尿的作用.中国中西医结合肾病杂志[J],2000,1(4),224-225
50.朱汉威,朱淳,陆玮,等.雷公藤多甙长程治疗肾小球肾炎疗效观察.上海第二医科大学学报[J],2002,22(6):543-544
51.Briggs WA,Choi MJ,Seheel PJ.Sueeessful myeo-phenolate mofetil treatment of glomerular disease.Am J Kidney Dis1998,1(2):213
52.冯为盛,姜继元.霉酚酸酯治疗难治性肾病综合征.中华肾脏病杂志[J],1999,15(5):287
53.黄茂芹,周森,陈裕盛.霉酚酸酯治疗肾病综合征8例观察.中华肾脏病杂志[J],2000,16(6):386
54.刘光陵,高远斌,夏正坤,等.霉酚酸酯在小儿肾小球疾病治疗中的应用效果.中华儿科杂志[J],1999,37(10):640
55沈平雁,蒋颈松.霉酚酸酯在治疗肾小球疾病中的应用.实用医学杂志[J],1999,15(9):731
56.Lou T,Wang C,Chen Z,et al.Randomised controlled trial of eflunomide in the treatment of immunoglobulin A nephropathy.Nephrology(Carlton),2006,11(2):113-116
57.王成,娄探奇,唐哗,等.来氟米特治疗难治性肾病综合征60例临床研究.中国实用内科杂志[J],2005,25(12):1096-1095
58.崔太根,侯凡凡,倪兆慧,等.来氟米特联合糖皮质激素治疗增殖型狼疮性肾炎的多中心对照临床试验研究.中华内科杂志[J],2005,44(9):672-676
59.任岳钦,李延国,马云航.来氟米特治疗过敏性紫癜性肾炎的临床研究.临床肾脏病杂志[J],2005,5(4):169-271
60.Metzler C,Fink C,LamPreeht P,et al.Maintenanee of remission with leflunomide in Wegener’s granulomatosis.Rheumatology(Oxford),2004,43(3):315-320
61. Xia ZK,Liu GL,Gao YF,e tal.FK506 in the treatment of children with nephritic syndrome of different pathologi-cal types[J].ClinePhrol,2006, 66(2):85-88.
62.Eisentack GM,et al.Kidney Int1975,8(1):
63.Ha H,Kim KH.Amelioration of diabetic microalbuinuria and lipid peroxidation by captopril.Yonsei Med J,1992,(33):217-273
64.Brien RC,PaPazoglou D,Allen T,et al.The effeets of perindopril versus triple therapy on albuminuria in normotensive diabetic rats.Kidney Int,1990,38:552-553
65.Marre M,Chatelier G,Lebiane N,et al.Prevention of diabetic nephopathy with enalapril in normotensive diabetes with mieroalbu-minuria.BMJ,1988,297:1092-1095
66Burnier M,Hagman M,Nussberger J,et al.Shor-Term and sustained renal effeets of angiotensinⅡre2 ceptor blockade in healthy subijeets. Hypertension,1995, 25(4partl):602
67.Chan JCN,Crisehey JAJH,Tomlinson B,et al.Antihypertensive and antial buminuric effects of losar2 tan potassium and felodipin in Chinese elderly hyper2 tensive patients with or without non-insulin-dePen2 dent diabetes mellitus.Am J Nephrol,1997,17:72
68.卞华.吕芹.李学铭教授治疗肾性蛋白尿的经验.国医论坛[J],2003,18(6):11
69.余立敏.从“肾虚毒损”治疗慢性肾炎蛋白尿血尿.中华中医药学刊[J],2007,25(5):972
70.莫湛宇,梁东,司徒玉,等.黄芪对肾病综合征患者氧化应激影响的研究[J].中国中西医结合肾病杂志,2004,5(4):209
71.李丽英,王海燕,朱进乐,等.黄芪当归对肾病综合征大鼠白蛋白的合成作用的研究[J].中华医学杂志,1995,75(5):276
72.朱南山,李丽立,张彬.党参的生物学功能及其应用前景.饲料工业,2006,(27)20:57-58
73.贺庆,朱恩圆,王峥涛.党参化学成分的研究.中医药学杂志,2006,4l(l):11-12
74苗明三,方晓艳.怀地黄多糖免疫兴奋作用的实验研究[J].中国中医药科技,2002,(3):159
75.徐强,王蓉,徐丽华,等.土茯苓对细胞兔疫和体液免疫的影响.中国免疫学杂志,1993,9(1):39
76.Zhang Yong-ciang,Xing-tian,Zho,Jin-huang.Effeets of L-ciumbar barum polysaeeharides and their combination with Corynebaeterium parvum on the tumoristaiic activity of peritoneal maerophages in mice[J].ChinaJphar Toxi,1989,3(3):169-174
77.董庆华,钟献,郑树.康莱特注射液对肺癌A549细胞环氧化酶作用的研究[J].中国中药杂志,2005,30(20):1621-1623
78.徐梓辉,周世文,黄文权,等.薏苡仁多糖对实验性糖尿病大鼠红细胞免疫、T淋巴细胞亚群的影响[J].湖南中医学院学报,2001,21(l):17-19
79.肖锦松,崔风军,宁廷选,等.玉竹、菟丝子醇提物对烧伤小鼠免疫功能的影响.中国中药杂志,1990,15(9):45-47
80.于庆海,杨丽君,孙启时,等.白茅根药理研究.中药材,1995,18(2):88
81.岳兴如,侯宗霞,刘萍,等.白茅根抗炎的药理作用.中国临床康复,2006,10(43):85
82.范美华,王健鑫,李鹏,等.益母草的研究进展[J].中国药物与临床,2006,6(7):528-529
83.徐勇,智光,郑思新.益母草的心血管药理作用及临床应用[J].世界急危重病医学杂志,2006,3(3):1312-1314
84.Frenk S.Experimental nephritie syndrome induced in rats by aminonueleoside.Proc Soe Exp Biol Med,1955,89:424-429
85.Diamond JR,Bonventre JV,Karnovski M.A role for oxygen free radieals in aminonueleoside nephrosis.Kidney Int,1986,29:478-483
86.Sternberg SS,Philips FS.BIPhasic intoxieation and nephritic syndrome in rats given daunomycin.Proe Amer Assoe Caneer Res,1967,8:64-70
87.Egido J,Ortiz A,Gomez-Chiarri M,et al.Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats:its pharmaeologieal modulation.Ren Fail,1991,13:95-101
88.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin induced ne-phrotic syndrome in rats.Lab Invest,1982,46:16-23
89.Newan David J,Pugia Miehael J,Lott John A,et al.Urinary protein andalbunin excretion correted by creatinine and speeifiegravity[J].Clinica Chimica Aeta,2000,294(1-2):139-155
90.Hartmann A,Jenssen T,Midtvedt K,e tal.Protein-crearinine ratio-a simple method for proteinuria assessment in clinieal practiee[J].Tidsskrift for Den Norske Laeggforening,2002,122(22):2180-2183
91.National Kidney Foundation.K/DOQI clinieal praetice guidelines for chronie kidney Disease:evaluation,clawwification and stratification[J].Am J Kidney Dis,2002,39(suppi):1-17
92.贺丹,柴华旗.黎曼.晨尿尿蛋白/尿肌酐比和24小时尿蛋白定量的临床评价.苏州大学学报(医学版).2004,24(6):861-863
93.Smoyer WE,Mundel P.Regulation of podoeyte scucture during the development of nephrotic syndrome.J Mbl Med,1998,76(3-4):172-183
94.Lemly KV,Lafayette RA,Ssfai M,et al.Podoeytopenia and disease Severity in IgA nephropathy[J]Kidney Int,2002,61(4):1475-1478
95.杜园园,黄朝兴.足突融合与IgA肾病肾小球硬化及蛋白尿的相关性分析.温州医学院学报,2007,37(3):247-249
96.Asanuma K,Mundel P.The role of podoeytes in glomerular pathobiology.Clin Ex PNePhrol,2003,7(4):255-259
97.Reiser J, von Gersdorff G, Simons M,et al.Novel concepts in understanding and Management of glomerular Proteinuria. NePhrin Dial Transplantat,2002,17(6):951-955.
98.Roselli S,Moutkine l,Gribouval O,et al. Plasma membrance targeting of podocin through the classical exocytic pathway: effect of NPHS2 mutations. Traffic,2004,5(l):37-44.
99.Schwarz K,Simons M,Reiser J,et al.Podocin,a raft-associated component of the Glomerular slit diaphragm, interacts with CD2AP and nephrin.J Clin Invest,2001,108(11):1621-9.
100.Saleem MA,Ni Lan,Witherden L,et al.Co-localization of nephrin,Podocin,and the actin cytoskeleton: Evidence for a role in Podocyte foot Process formation. Am J Pathlo,2002,161(4):1459-1466.
101.FanQ,Ding J,Zhang J,et al.Effect of the knockdown of PodocinmRNA on nephrin And alpha-actinin in mouse Podocyte. Exp Biol Med (Maywood).2004,229(9):964-70.
102.Huber TB,Simons M,Hartleben B,et al.Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains .Hum Mol Genet. 2003,12(24):3397-405.
103.Nishibori Y, Liu L,Hosoyamada M,et al. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the Plasma membrance. Kindney Int,2004,66(5):1755-65.
104.Huber TB,Kottgen M,Schilling B,Walz G, Benzing T.Interacrtion with podocin Facilitates nephrin signaling. J Biol Chem,2001,276(45):41543-6.
105. Sako M, Nakanishi K, Obana M,et al. Analysis of NPHS1, NPHS2,ACTN4, and WT1 in Japanese patients with congenital nephrotic syn-drome[J].Kidney Int, 2005, 67(4): 1248-1255.
106.于力,温捷,赵丹,等. nephrin分子在多柔比星肾小球硬化大鼠模型中的表达[ J].实用儿科临床杂志, 2007, 22(17): 1299-1301.
107 .HuberTB, SchermerB,MullerRU,etal. Podocin andmec-2 bind cho-lesterol to regulate the activity of associated ion channels[J].ProcNatlAcad SciUSA, 2006, 103(46): 17079-17086.
108.Huber TB, SchermerB, BenzingT. Podocin organizes ion channel-lipidsupercomplexes: Implications formechanosensation at the slit diaphragm[J].Nephron ExpNephrol2007, 106(2): e27-e31.
109.ShonoA,TsukaguchiH,Yaoita E,et al. Podocin participates in the as-sembly of tight junctions between foot processes in nephrotic podocytes[J].JAm SocNephrol, 2007, 18(9): 2525-2533.
110.diDucaM,OlegginiR, Sanna-CherchiS,etal.Cis and trans regulatoryelements inNPHS2 promoter: Implications in proteinuria and progressionof renal diseases[J].Kidney Int, 2006, 70(7): 1332-1341.
111.Oleggini R, Bertelli R, di Donato A,et al. Rare functional variants ofpodocin (NPHS2) promoter in patients with nephrotic syndrome[ J].GeneExpr, 2006, 13(1): 59-66.
112. BerdeliA,Mir S, Yavascan O,et al. NPHS2 (podicin) mutations in·1337·实用儿科临床杂志第23卷第17期2008年9月J ApplClinPediatr,Vol.23No.17,Sep.2008Turkish children with idiopathic nephrotic syndrome[J].PediatrNeph-rol, 2007, 22(12): 2031-2040.
113. McKenzie LM,Hendrickson SL, BriggsWA,et al.NPHS2 variation insporadic focal segmental glomerulosclerosis[ J].J Am Soc Nephrol,2007, 18: 2987-2995.
114. PhilippeA,WeberS,EsquivelEL,etal.Amissensemutation in podo-cin leads to early and severe renal disease in mice[ J].Kidney Int,2008, 73(9): 1038-1047.
115.KoopK,EikmansM,BaeldeHJ,etal.Expression of podocyte-associa-tedmolecules in acquired human kidney diseases[J].JAm SocNeph-rol, 2003, 14(8): 2063-2071.
116.Mao J, ZhangY,DuL,etal.Expression profile ofnephrin, podocin, andCD2AP in Chinese children withMCNS and IgA nephropathy[J].Pe-diatrNephrol, 2006, 21(11): 1666-1675.
117.夏珣,鹿玲,王明丽.多柔比星肾病大鼠podocinmRNA表达与氧化应激反应的关系[J].实用儿科临床杂志, 2007, 22(5): 340-342.
118.XingY,Ding J, FanQ,etal.Diversities of podocytemolecular changesinduced by different antiproteinuria drugs[ J].Exp BiolMed (May-wood), 2006, 231(5): 585-593.
119.Shibata S,NagaseM, Fujita T. Fluvastatin ameliorates podocyte injuryin proteinuric rats viamodulation of excessive rho signaling[J].JAmSocNephrol, 2006, 17(3): 754-764.
2.张路霞,左力,徐国宾等.北京市石景山地区中老年人群中慢性肾脏病的流行病学研究.中华肾脏病杂志[J],2006,22(2):67-71
3.仝小林,张志远.蛋白尿的中医治疗.中国医药学报[J],2002,17(2):115
4.刘伟,贝岩.中药辨证治疗蛋白尿探析.辽宁中医杂志[J],2005,32(3):225
5.李亦聪,冯天保.谢桂权教授治疗慢性肾炎蛋白尿经验介绍.新中医[J],2006,38(4):16
6.张琼.黄淑芬从络病论治肾性蛋白尿.中医杂志[J],2004,46(10):745
7.沈庆法.清利法治疗蛋白尿.上海中医药杂志[J],2006,40(2):23
8.袁红霞.林嫦娥.黄文政教授治疗顽固性蛋白尿经验总结.天津中医药[J],2003,20(5):18-19
9.刘宏伟,王国栋,张国强.国医时振声教授学术贡献撷萃.中医药学刊[J],2001,19(6):534
10.郭立中,毛炜,刘玉宁,等.叶传惠教授对肾炎蛋白尿的病机认识及治疗经验.中国中西医结合肾病杂志[J],2001,2(3):128
11.邓聪.从风郁瘀论治蛋白尿.中华中医药杂志[J],2006,21(8):506
12.代渊.唐章全主任医师治疗慢性肾蛋白尿经验.中医药学刊[J] , 2006 ,24(3):408-409
13.邹玺.熊宁宁.长期应用清热利湿和络法对慢性肾炎患者蛋白尿变化的影响.中医杂志[J], 2004,45(4):266-269
14.方志传.养脾为主治疗慢性肾炎蛋白尿.湖北中医杂志[J],2001,23(8):346
15.张丽霞.升阳益气固肾化瘀治疗慢性肾炎蛋白尿疗效观察.中医药学刊[J],2006,24(5):965-966
16.李玉花.活血化瘀法在蛋白尿治疗中的运用.实用中西医结合临床[J],2005,(5)2:55-56
17.王静.补肾固涩法为主治疗蛋白尿30例.陕西中医[J],2001,22(10):590
18.齐占华.益肾液治疗肾小球性蛋白尿疗效分析.实用中医药杂志[J],2005,21(10):585
19.练建红.刘恩棋.蒙向欣等.益肾I方治疗肾小球性蛋白尿的临床研究.福建中医药[J],2007,3(3):1-3
20.雷作熹,罗仁,董晓蕾等.小四五颗粒对糖尿病大鼠肾保护作用研究[J].中药新药与临床药理[J],2003,14(2):93-96
21.代方国.魏敏.孙晓敏,等.小四五颗粒治疗慢性肾病蛋白尿30例临床观察[J].新中医,2007,39(8):33-34
22.何岚.王宁生.五苓散减轻阿霉素肾病大鼠蛋白尿的实验研究.中成药[J],2006,28(10):1532-1534
23.赵飞,王晓霞,程广清等.疏血通注射液治疗肾性蛋白尿69例临床观察[J]山东中医药大学学报,2007,31(4):294-295
24.张万祥,秦建国,张荣等.参芪益肾汤治疗疗肾性蛋白尿45例观察.时珍国医国药,2007,18(6):1482-1483
25.曾红兵,刘晓城.火把花根对实验性肾炎大鼠肾脏病理改变的影响.中国中西医结合肾病杂志[J].2006,(7)1:13-15
26.陈志强,方敬,刘丽,等.青藤碱对系膜增生性肾小球肾炎影响的实验研究[J].中国老年学杂志,2007,27:27-28
27.Mundel P,Shankland SJ.Podocyte biology and resPonse toinjury.J Am Soe NePlirol,2002,13(12):3005-3015
28.Yuzawa Y,Matsuo S.Focal segmental glomerulosclerosis.Nippon Rinsho,2004,62 (10):1837-1841
29.Bariety J,Bruneval P.Hill G,et al.Posttransplantation relapse of FSGS is charaeterized by glomemlar epithelial cell transdifferentieatlon[J].J Am Soe Nephol,2001,12(2):261-274
30.Huber TB,Hardeben B,Kim J,et al.Nephrin and CD2AP associate with Phosphoinositide 3-OH kinase and stimulate AKT-dependent signaiing[J].MolCel lBiol,2003,23(14):4917-4928
31.Cantley LC.The phosphoinositide3-kinase pathway[J].Seienee,2002,296(5573):1655~1657
32.Kaplan JM,Kim SH,North KN, e tal.Mutations in ACTN4,encoding alpha-aetinin-4,cause familial foeal segmental glomerulaselerosis[J].NatGenet,2000,24:251-256
33.Yao J,Le TC,Kos CH,et al.AIPha-actinin-4- mediated FSGS:an inherited kidney disease caused by an aggre-gated and rapidly degraded cytaskeletal protein[J] Plos Biol,2004,2(6):787-794
34.Weins A,Kenlan P,Herbert S,et al.Mutational and Bio-logieal Analysis of alpha-actinin-4 in focal segmental glomeruloselerosis[J].J Am Soe Nephrol.2005,16(12):3694-3701
35.Luimula P,Sandstrom N,Novikon D et al.Podoeyte-assoeiated moleeules in puromycm aminonueleaside nephrosis of therat[J].LabInvest,2002,82(6):713-718
36.何伟春,邢昌赢,孙彬,等.CD2AP和α-actinin-4在大鼠阿霉素肾病模型中的表达.南京医科大学学报(自然科学版),2006,26(11):1005-1007
37.Boute N.Gribouval O.Roselli S.et al.NPHS2.encoding the gomerular protein Podoein,is mutated in autosomal recessive steroid- resistant nephritic syndrome.Nat Genet2000,24:349-354
38.Sehwarz K.Simons M.Keiser,J.et al.Podoein,araft-assoeiated component of the gomemlar slit diaphragm,interacts with CD2AP and nephrin.J Clin Invest,2001,108(11):1621-1629
39.Sedeuskv MM.Siefker,JM.Mordel organisms:new insights into charnel and transporter function.Stomatiu homologues interaet in Caeuorhahditis elegans. Am,J Physiol Cell Phvsiol.2001,280.C1340-C134R
40.叶任高,沈清瑞.肾脏病诊断与治疗学.北京:北京人民卫生出版社[M],1994:208
41.叶任高,刘冠贤.临床肾脏病学.北京:北京人民卫生出版社[M],1997:52-53
42.林善琐,陈靖.肾小球疾病治疗最新进展.中国实用内科杂志,2000,20:26-29
43.Edited by Barry M.Brenner The kidneyy[J] .Science press sixth dition,2000,1271-1277
44.Albert Matalon,Anthong Valeri,and Grerald B Appel:Treatment of Focal segmental Glomerulosclerosis[J] .Seminars in Nephrology.2000,20:309-317
45.何敏华,叶任高,马翅云.糖皮质激素在肾小球疾病治疗中的进展.大理学院学报[J],2003,(2)3:52
46.李幼姬,叶任高,姜搅.成人原发性肾病综合征治疗的探索.中华肾脏病杂志[J],1995,11(3):133-136
47.黎磊石,张训,陈光永,等.雷公藤治疗肾小球肾炎的临床研究.中华内科杂志[J],1981,20(4):216
48.黎磊石,刘志红.雷公藤在肾脏病领域应用的前景.肾脏病与透析肾移植杂志[J],1997,6(3):203
49.施向东,范德墉,陆玉良.雷公藤多甙片对肾性蛋白尿的作用.中国中西医结合肾病杂志[J],2000,1(4),224-225
50.朱汉威,朱淳,陆玮,等.雷公藤多甙长程治疗肾小球肾炎疗效观察.上海第二医科大学学报[J],2002,22(6):543-544
51.Briggs WA,Choi MJ,Seheel PJ.Sueeessful myeo-phenolate mofetil treatment of glomerular disease.Am J Kidney Dis1998,1(2):213
52.冯为盛,姜继元.霉酚酸酯治疗难治性肾病综合征.中华肾脏病杂志[J],1999,15(5):287
53.黄茂芹,周森,陈裕盛.霉酚酸酯治疗肾病综合征8例观察.中华肾脏病杂志[J],2000,16(6):386
54.刘光陵,高远斌,夏正坤,等.霉酚酸酯在小儿肾小球疾病治疗中的应用效果.中华儿科杂志[J],1999,37(10):640
55沈平雁,蒋颈松.霉酚酸酯在治疗肾小球疾病中的应用.实用医学杂志[J],1999,15(9):731
56.Lou T,Wang C,Chen Z,et al.Randomised controlled trial of eflunomide in the treatment of immunoglobulin A nephropathy.Nephrology(Carlton),2006,11(2):113-116
57.王成,娄探奇,唐哗,等.来氟米特治疗难治性肾病综合征60例临床研究.中国实用内科杂志[J],2005,25(12):1096-1095
58.崔太根,侯凡凡,倪兆慧,等.来氟米特联合糖皮质激素治疗增殖型狼疮性肾炎的多中心对照临床试验研究.中华内科杂志[J],2005,44(9):672-676
59.任岳钦,李延国,马云航.来氟米特治疗过敏性紫癜性肾炎的临床研究.临床肾脏病杂志[J],2005,5(4):169-271
60.Metzler C,Fink C,LamPreeht P,et al.Maintenanee of remission with leflunomide in Wegener’s granulomatosis.Rheumatology(Oxford),2004,43(3):315-320
61. Xia ZK,Liu GL,Gao YF,e tal.FK506 in the treatment of children with nephritic syndrome of different pathologi-cal types[J].ClinePhrol,2006, 66(2):85-88.
62.Eisentack GM,et al.Kidney Int1975,8(1):
63.Ha H,Kim KH.Amelioration of diabetic microalbuinuria and lipid peroxidation by captopril.Yonsei Med J,1992,(33):217-273
64.Brien RC,PaPazoglou D,Allen T,et al.The effeets of perindopril versus triple therapy on albuminuria in normotensive diabetic rats.Kidney Int,1990,38:552-553
65.Marre M,Chatelier G,Lebiane N,et al.Prevention of diabetic nephopathy with enalapril in normotensive diabetes with mieroalbu-minuria.BMJ,1988,297:1092-1095
66Burnier M,Hagman M,Nussberger J,et al.Shor-Term and sustained renal effeets of angiotensinⅡre2 ceptor blockade in healthy subijeets. Hypertension,1995, 25(4partl):602
67.Chan JCN,Crisehey JAJH,Tomlinson B,et al.Antihypertensive and antial buminuric effects of losar2 tan potassium and felodipin in Chinese elderly hyper2 tensive patients with or without non-insulin-dePen2 dent diabetes mellitus.Am J Nephrol,1997,17:72
68.卞华.吕芹.李学铭教授治疗肾性蛋白尿的经验.国医论坛[J],2003,18(6):11
69.余立敏.从“肾虚毒损”治疗慢性肾炎蛋白尿血尿.中华中医药学刊[J],2007,25(5):972
70.莫湛宇,梁东,司徒玉,等.黄芪对肾病综合征患者氧化应激影响的研究[J].中国中西医结合肾病杂志,2004,5(4):209
71.李丽英,王海燕,朱进乐,等.黄芪当归对肾病综合征大鼠白蛋白的合成作用的研究[J].中华医学杂志,1995,75(5):276
72.朱南山,李丽立,张彬.党参的生物学功能及其应用前景.饲料工业,2006,(27)20:57-58
73.贺庆,朱恩圆,王峥涛.党参化学成分的研究.中医药学杂志,2006,4l(l):11-12
74苗明三,方晓艳.怀地黄多糖免疫兴奋作用的实验研究[J].中国中医药科技,2002,(3):159
75.徐强,王蓉,徐丽华,等.土茯苓对细胞兔疫和体液免疫的影响.中国免疫学杂志,1993,9(1):39
76.Zhang Yong-ciang,Xing-tian,Zho,Jin-huang.Effeets of L-ciumbar barum polysaeeharides and their combination with Corynebaeterium parvum on the tumoristaiic activity of peritoneal maerophages in mice[J].ChinaJphar Toxi,1989,3(3):169-174
77.董庆华,钟献,郑树.康莱特注射液对肺癌A549细胞环氧化酶作用的研究[J].中国中药杂志,2005,30(20):1621-1623
78.徐梓辉,周世文,黄文权,等.薏苡仁多糖对实验性糖尿病大鼠红细胞免疫、T淋巴细胞亚群的影响[J].湖南中医学院学报,2001,21(l):17-19
79.肖锦松,崔风军,宁廷选,等.玉竹、菟丝子醇提物对烧伤小鼠免疫功能的影响.中国中药杂志,1990,15(9):45-47
80.于庆海,杨丽君,孙启时,等.白茅根药理研究.中药材,1995,18(2):88
81.岳兴如,侯宗霞,刘萍,等.白茅根抗炎的药理作用.中国临床康复,2006,10(43):85
82.范美华,王健鑫,李鹏,等.益母草的研究进展[J].中国药物与临床,2006,6(7):528-529
83.徐勇,智光,郑思新.益母草的心血管药理作用及临床应用[J].世界急危重病医学杂志,2006,3(3):1312-1314
84.Frenk S.Experimental nephritie syndrome induced in rats by aminonueleoside.Proc Soe Exp Biol Med,1955,89:424-429
85.Diamond JR,Bonventre JV,Karnovski M.A role for oxygen free radieals in aminonueleoside nephrosis.Kidney Int,1986,29:478-483
86.Sternberg SS,Philips FS.BIPhasic intoxieation and nephritic syndrome in rats given daunomycin.Proe Amer Assoe Caneer Res,1967,8:64-70
87.Egido J,Ortiz A,Gomez-Chiarri M,et al.Involvement of lipid mediators in the pathogenesis of experimental nephrosis in rats:its pharmaeologieal modulation.Ren Fail,1991,13:95-101
88.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin induced ne-phrotic syndrome in rats.Lab Invest,1982,46:16-23
89.Newan David J,Pugia Miehael J,Lott John A,et al.Urinary protein andalbunin excretion correted by creatinine and speeifiegravity[J].Clinica Chimica Aeta,2000,294(1-2):139-155
90.Hartmann A,Jenssen T,Midtvedt K,e tal.Protein-crearinine ratio-a simple method for proteinuria assessment in clinieal practiee[J].Tidsskrift for Den Norske Laeggforening,2002,122(22):2180-2183
91.National Kidney Foundation.K/DOQI clinieal praetice guidelines for chronie kidney Disease:evaluation,clawwification and stratification[J].Am J Kidney Dis,2002,39(suppi):1-17
92.贺丹,柴华旗.黎曼.晨尿尿蛋白/尿肌酐比和24小时尿蛋白定量的临床评价.苏州大学学报(医学版).2004,24(6):861-863
93.Smoyer WE,Mundel P.Regulation of podoeyte scucture during the development of nephrotic syndrome.J Mbl Med,1998,76(3-4):172-183
94.Lemly KV,Lafayette RA,Ssfai M,et al.Podoeytopenia and disease Severity in IgA nephropathy[J]Kidney Int,2002,61(4):1475-1478
95.杜园园,黄朝兴.足突融合与IgA肾病肾小球硬化及蛋白尿的相关性分析.温州医学院学报,2007,37(3):247-249
96.Asanuma K,Mundel P.The role of podoeytes in glomerular pathobiology.Clin Ex PNePhrol,2003,7(4):255-259
97.Reiser J, von Gersdorff G, Simons M,et al.Novel concepts in understanding and Management of glomerular Proteinuria. NePhrin Dial Transplantat,2002,17(6):951-955.
98.Roselli S,Moutkine l,Gribouval O,et al. Plasma membrance targeting of podocin through the classical exocytic pathway: effect of NPHS2 mutations. Traffic,2004,5(l):37-44.
99.Schwarz K,Simons M,Reiser J,et al.Podocin,a raft-associated component of the Glomerular slit diaphragm, interacts with CD2AP and nephrin.J Clin Invest,2001,108(11):1621-9.
100.Saleem MA,Ni Lan,Witherden L,et al.Co-localization of nephrin,Podocin,and the actin cytoskeleton: Evidence for a role in Podocyte foot Process formation. Am J Pathlo,2002,161(4):1459-1466.
101.FanQ,Ding J,Zhang J,et al.Effect of the knockdown of PodocinmRNA on nephrin And alpha-actinin in mouse Podocyte. Exp Biol Med (Maywood).2004,229(9):964-70.
102.Huber TB,Simons M,Hartleben B,et al.Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains .Hum Mol Genet. 2003,12(24):3397-405.
103.Nishibori Y, Liu L,Hosoyamada M,et al. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the Plasma membrance. Kindney Int,2004,66(5):1755-65.
104.Huber TB,Kottgen M,Schilling B,Walz G, Benzing T.Interacrtion with podocin Facilitates nephrin signaling. J Biol Chem,2001,276(45):41543-6.
105. Sako M, Nakanishi K, Obana M,et al. Analysis of NPHS1, NPHS2,ACTN4, and WT1 in Japanese patients with congenital nephrotic syn-drome[J].Kidney Int, 2005, 67(4): 1248-1255.
106.于力,温捷,赵丹,等. nephrin分子在多柔比星肾小球硬化大鼠模型中的表达[ J].实用儿科临床杂志, 2007, 22(17): 1299-1301.
107 .HuberTB, SchermerB,MullerRU,etal. Podocin andmec-2 bind cho-lesterol to regulate the activity of associated ion channels[J].ProcNatlAcad SciUSA, 2006, 103(46): 17079-17086.
108.Huber TB, SchermerB, BenzingT. Podocin organizes ion channel-lipidsupercomplexes: Implications formechanosensation at the slit diaphragm[J].Nephron ExpNephrol2007, 106(2): e27-e31.
109.ShonoA,TsukaguchiH,Yaoita E,et al. Podocin participates in the as-sembly of tight junctions between foot processes in nephrotic podocytes[J].JAm SocNephrol, 2007, 18(9): 2525-2533.
110.diDucaM,OlegginiR, Sanna-CherchiS,etal.Cis and trans regulatoryelements inNPHS2 promoter: Implications in proteinuria and progressionof renal diseases[J].Kidney Int, 2006, 70(7): 1332-1341.
111.Oleggini R, Bertelli R, di Donato A,et al. Rare functional variants ofpodocin (NPHS2) promoter in patients with nephrotic syndrome[ J].GeneExpr, 2006, 13(1): 59-66.
112. BerdeliA,Mir S, Yavascan O,et al. NPHS2 (podicin) mutations in·1337·实用儿科临床杂志第23卷第17期2008年9月J ApplClinPediatr,Vol.23No.17,Sep.2008Turkish children with idiopathic nephrotic syndrome[J].PediatrNeph-rol, 2007, 22(12): 2031-2040.
113. McKenzie LM,Hendrickson SL, BriggsWA,et al.NPHS2 variation insporadic focal segmental glomerulosclerosis[ J].J Am Soc Nephrol,2007, 18: 2987-2995.
114. PhilippeA,WeberS,EsquivelEL,etal.Amissensemutation in podo-cin leads to early and severe renal disease in mice[ J].Kidney Int,2008, 73(9): 1038-1047.
115.KoopK,EikmansM,BaeldeHJ,etal.Expression of podocyte-associa-tedmolecules in acquired human kidney diseases[J].JAm SocNeph-rol, 2003, 14(8): 2063-2071.
116.Mao J, ZhangY,DuL,etal.Expression profile ofnephrin, podocin, andCD2AP in Chinese children withMCNS and IgA nephropathy[J].Pe-diatrNephrol, 2006, 21(11): 1666-1675.
117.夏珣,鹿玲,王明丽.多柔比星肾病大鼠podocinmRNA表达与氧化应激反应的关系[J].实用儿科临床杂志, 2007, 22(5): 340-342.
118.XingY,Ding J, FanQ,etal.Diversities of podocytemolecular changesinduced by different antiproteinuria drugs[ J].Exp BiolMed (May-wood), 2006, 231(5): 585-593.
119.Shibata S,NagaseM, Fujita T. Fluvastatin ameliorates podocyte injuryin proteinuric rats viamodulation of excessive rho signaling[J].JAmSocNephrol, 2006, 17(3): 754-764.